Genzyme snags fast-track designation for Fabry drug; PTC advances a cancer treatment;

@FierceBiotech: ICYMI yesterday: Celgene bags a build-to-buy biotech in $485M cancer deal. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CEO Scangos commits $2.5B to a high stakes Alzheimer's gamble. More | Follow @JohnCFierce

> Sanofi's ($SNY) Genzyme business scored the FDA's fast-track designation for GZ/SAR402671, a Phase II treatment for the rare Fabry disease. More

> PTC Therapeutics ($PTCT) kicked off a Phase I study for PTC596, an oral cancer treatment targeting the protein BMI1. News

> Cerulean Pharma ($CERU) picked up a fast-track nod for CRLX101, a nanoparticle-drug conjugate designed to treat renal cancer in combination with Roche's ($RHHBY) Avastin. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Two U.S. hospitals to test startup's novel medical device malware detection software. Article | Follow @FierceMedDev

@VarunSaxena2: FDA bans manufacturing of Medtronic's infusion pump, citing violation of quality system regs. News | Follow @VarunSaxena2

@EmilyWFierce: Scanadu ropes in $35M for smartphone tricorder diagnostic device. More | Follow @EmilyWFierce

> Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system. Story

> 'Stealthy' Medina raises $6M in debt for cerebral aneurysm device after CE mark last fall. Article

Pharma News

@FiercePharma: Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Would any of you guys want to read a special report entitled "The secret first initials of biopharma CEOs and what they stand for"...? | Follow @CarlyHFierce

> Flush with Q1 success, Merck touts coming launches in hep C, lung cancer. Story

> It's official: Takeda to pay a 'bargain' $2.3B to settle Actos lawsuits. Article

Drug Delivery News

> Presage's multiple-cancer-drug injection device shows promising first-in-human results. Story

> Topical gel for migraine shows promise in trials, can penetrate transdermal barrier. Item

> 3M says its new intravenous port dressing will make drug delivery easier and fight off site infections. Report

> AbbVie's FDA-approved Duopa gel for Parkinson's skates through yearlong study. Story

> Generex announces second medical marijuana outlicensing deal for its drug delivery tech. Article

Pharma Manufacturing News

> Texas cancer center guilty of selling foreign-made Avastin. Item

> Wockhardt recalling all pre-ban products still in the U.S. More

> Mylan recalls injected cancer meds made for Pfizer. Story

> GSK licks Nicorette manufacturing problems; 'Minis' are back. Article

> Lilly's Elanco to unload former Novartis vax plant. News

Pharma Asia News

> Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies. Report

> India mulls adopting international standards on drug inspections, manufacturing. Story

> Cipla leans toward compromise in India court case over Onbrez from Novartis. More

> Japan's Panasonic joins Toshiba in rush to medical devices. Article

> Daiichi Sankyo has solid chance to pare debt, reinvest on Sun stake sale, Moody's says. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.